Medical devices, healthcare technology and the business of care
FDA RECALL RECORD · Z-0513-2027

OptiCross 35 Peripheral Imaging Catheter, Material Numbers/UPN: H7493932800350, H7493932801350, H7493932802350 Recall

OptiCross 35 Peripheral Imaging Catheter, Material Numbers/UPN: H7493932800350, H7493932801350, H7493932802350

FDA recall Class II

Open , Classified

FDA lists this Class II recall for OptiCross 35 Peripheral Imaging Catheter, Material Numbers/UPN: H7493932800350, H7493932801350, H7493932802350. Review the affected identifiers, reported reason and manufacturer instructions below.

Recall at a glance

Recall number
Z-0513-2027
Recall classification
Class II
FDA database status
Open , Classified
Initiation date
Oct 22, 2026
FDA website posting date
Nov 20, 2026
Quantity in commerce
1,288,662 total units
Distribution
See key details
FDA cause
Not reported

What is being recalled?

OptiCross 35 Peripheral Imaging Catheter, Material Numbers/UPN: H7493932800350, H7493932801350, H7493932802350

Affected model & UDI checker

Search the exact identifiers published for Z-0513-2027.

The lookup covers structured identifiers listed on this page. A full UDI may also contain lot or serial information; a GTIN match alone does not check those conditions.

Affected products

Model / catalog numberProductLot scope reportedUDI / GTIN
Not specifiedOptiCross 35 Peripheral Imaging Catheter, Material Numbers/UPN: H7493932800350, H7493932801350, H7493932802350Check source notice08714729984542
Not specifiedOptiCross 35 Peripheral Imaging Catheter, Material Numbers/UPN: H7493932800350, H7493932801350, H7493932802350Check source notice08714729997153
Not specifiedOptiCross 35 Peripheral Imaging Catheter, Material Numbers/UPN: H7493932800350, H7493932801350, H7493932802350Check source notice08714729997160
FDA code information

GTIN: 08714729984542, 08714729997153, 08714729997160; All non-expired batches

View the original FDA recall notice

Why was this product recalled?

IFU updates in response to reports of air embolism events and reports of repeated flushing to restore image quality while the catheter was positioned within the patient. Intravascular air may cause air embolism, resulting in clinical consequences of varying severity, including ST-segment changes, reduced blood flow, arrhythmia, myocardial infarction, cardiac arrest, and other serious injury.

What actions did Boston Scientific Corporation take?

An Important Medical Device Advisory dated 10/22/26 was sent to customers. Required Action "Review IFU updates related to air embolism as detailed in Appendix 1. "Follow these steps when using OptiCross IVUS catheters: oComplete all device preparation and flushing instructions before inserting the catheter into the patient. This includes clearing air from all accessories and then the catheter by completing all three IFU-prescribed flushing steps. oDo not flush the OptiCross IVUS catheter while it is positioned within the patient if entrapped air is suspected. If additional flushing is required, remove the catheter from the patient before flushing. "Forward this notice to relevant personnel and any facilities to which the product was transferred. If you are a distributor, forward this notice to your customers. "Post this information in a visible location near the affected products to ensure it is readily available to all users of the device. "Complete and return the enclosed Acknowledgement Form. If you require additional assistance or more information regarding this communication, please contact your local Boston Scientific representative.

Read the manufacturer action recorded by FDA

Recall timeline

  1. Recall initiated by firm

  2. FDA notice posted

Related FDA submissions

No submission number with an exact verified relationship is linked in the retrieved recall notice.

FDA’s notice explicitly links the submission numbers shown here. Read each filing for its own recorded device and scope.

Source and update history

The history starts with the versions held by MedtechLedger. Earlier source changes are not reconstructed. Official dates and recorded status come from FDA; page summaries describe the source information.

Our data sources and methodology